Join the club for FREE to access the whole archive and other member benefits.

Cirrus Therapeutics

Ocular immunology-focused company

Cirrus Therapeutics is an ocular immunology-focused company developing treatments for long-term eye diseases that can cause blindness, focusing on conditions that affect the ocular immune system. This company is a spin-out from the University of Bristol.

The company's lead program is a differentiated and first-in-class approach to treating dry age-related macular degeneration (AMD), the leading cause of vision loss among older adults.

Cirrus’ novel approach not only addresses the multiple pathways involved in treating AMD but also offers the most compelling and evidence-based strategy available today.

Visit website:


See also: Academia University of Bristol - Leading UK university researching infection, human rights, climate change, and information security.

Details last updated 07-Jul-2024

Cirrus Therapeutics News

New protein therapy holds promise to combat age-related visionloss

Ophthalmology Times - 07-Jun-2024

Boosting IRAK-M protein protects retinal cells in AMD patients